Recent molecular studies provide important clues into treatment of β-thalassemia, sickle-cell anaemia and other β-globin disorders revealing that increased production of fetal hemoglobin, that is normally suppressed in adulthood, can ameliorate the severity of these diseases. In this paper, we present a novel approach for drug target prediction for β-globin disorders. Our approach is centered upon quantitative modelling of interactions in human fetal-to-adult hemoglobin switch network using hybrid functional Petri nets. In accordance with the reverse pharmacology approach we pose a hypothesis regarding modulation of specific protein targets that induce γ-globin and consequently fetal hemoglobin. Comparison of simulation results for the proposed strategy with the ones obtained for already existing drugs shows that our strategy is the optimal as it leads to highest level of γ-globin induction and thereby has potential beneficial therapeutic effects on β-globin disorders. Simulation results enable verification of model coherence demonstrating that it is consistent with qPCR data available for known strategies and/or drugs.
Introduction
β-thalassemia, sickle-cell anaemia and other β-globin disorders caused by mutations in adult hemoglobin (HbA) are among most common genetic disorders in the world. According to the recent estimates, hundreds of thousands of children with these diseases are born every year, and there are tens of millions of patients with these disorders in the world. It was also reported that these diseases are among major sources of mortality worldwide [1] . The prevalence of these diseases is expected to rise dramatically over the next century as the world's population grows. Therefore, developing improved treatment for these disorders is of utmost interest.
The current curative therapies and treatments for these diseases involve bone marrow transplantation [2] , gene therapy [3] , and symptomatic care followed by transfusion of red blood cells as it is clinically necessary [4] . Numerous Figure 2. The switch from fetal to adult hemoglobin is regulated by numerous biological components. Positive and negative interactions between these components are denoted by regular and blunted arrows, respectively. Regulators of this process are potential therapeutic targets for patients with β-globin disorders. Circle surrounding a biological component indicates number of the strategy that targets specified component. illustrated in Fig. 1 and Fig. 2 , respectively. In the beginning of the first three months, there is robust expression of an embryonic form of a β-globin known as ε-globin [24] . Concurrently while, when ε-globin starts being down regulated, the β-like globin molecule known as γ-globin is produced [25] . This is known as embryonic-to-fetal hemoglobin switch, which is the first developmental switch in expression of human globin genes. γ-globin remains the predominant hemoglobin for much of gestation until after birth. Close to the end of third month ε-globin is almost completely silenced. This event is followed by up regulation of β-globin gene. The second developmental switch in expression of human hemoglobin known as fetal-to-adult hemoglobin switch takes place around time of birth. This event triggers increase of HbA production and decrease of HbF production.
BCL11A is the major protein that represses the expression of γ-globin genes [23] . It was observed that down regulation of BCL11A robustly induces γ-globin gene expression [14] . Its protein partners, including HDAC1/2 and GATA1 contribute to repression of γ-globin gene by binding to BCL11A [26] . KLF1 contributes to this process by positively regulating the expression of BCL11A [14] . KLF1 also promotes transcription of β-globin gene. Additionally, it has been reported that the transcription factor SOX6 cooperates with BCL11A to silence the γ-globin genes in humans [27] . 
Petri Nets
In context of biological systems Petri net is a bipartite graph composed of two types of nodes, places and transitions; the former being suitable for representing biological entities, and the latter biological phenomena. In such a net, the arcs connect places with transitions or vise versa, and keep information on reaction stoichiometry. The places encode the molecular concentration. Continuity is perhaps the only characteristic that distinguishes Petri nets 3
/ Procedia Computer Science 00 (2016) 1-12 4 for biological systems from classical or original ones. In continuous Petri nets each transition has detailed information about the kinetics of the related biochemical reaction. Biological systems are characterized by often interaction between different structured processes. It is quite regular that a Petri net model of biological system comprises continuous, boolean and discrete processes. For instance, biochemical reactions are continuous processes, while the presence/absence of a biological phenomenon is a boolean process. A counter-like mechanism on the other hand is a typical discrete process. HFPN is inherited from hybrid Petri net in which a function is associated with each continuous process. HFPN has been successfully implemented to modelling and simulating of various biological processes [28] [29] [30] [31] . 
Creating the model
We create HFPN model of human fetal-to-adult hemoglobin switch network in accordance with biological context extracted from the literature [14, 23, 26, 27] . In this model, it is assumed that major proteins are made up by the central dogma of molecular biology, so that mRNA transcribed from DNA is then translated into protein. It is also supposed that the mRNA and protein levels are kept low by natural degradation. Tables I-IV. In molecular biology, it is quite regular that two identical experiments lead to not identical observations. Unfortunately, wet lab results for certain biological phenomena are scarce and sometimes contradictory. This is why it is rather cumbersome task to determine kinetic parameters such as reaction rates based on wet lab results only. In this work, we set the rates of biological phenomena in accordance with [28] [29] [30] [31] , and then carefully calibrate them to validate the model of fetal-to-adult hemoglobin switch network with available qPCR data for wild type β-globin gene ( Fig. 1-2 ). The process rates adopted in the present research are presented in Table II . 
Computational validation of the model
In the present research, we use Cell Illustrator software to create HFPN model of human fetal-to-adult hemoglobin switch network and perform simulations to validate the model. Validation is achieved through altering calibration 5 T36 Continuous m18*1.9 0 Binding of ETF and its inhibitor T37 Continuous m20*0.12 0 parameters (e.g., process rates and initial concentrations), and comparing validation parameters (e.g., gene, mRNA and protein concentrations) to the wet lab observations. The concentrations (y-axis) are plotted against time units (xaxis) called Petri time or pt, for short. In these plots, each 10 pt in the time axis corresponds to 3 months of gestational age, so we suppose that fetal life starts at 20 pt (0 months), and that a child is born at 50 pt (9 months). We gather results for γ-globin gene induction at 70 pt, that is, 6 months after the birth. In order to obtain the closest approximation of concentration levels of wild type β-globin mRNA and γ-globin mRNA ( Fig. 1) we started validating our model by extrapolating simulation results for wild type β-globin mRNA and γ-globin mRNA on the basis of their relationship with biological components involved in human fetal-to-adult hemoglobin switch network in Fig. 2 . Simulation results for expression of wild type β-globin mRNA and γ-globin mRNA are illustrated in Fig. 6 . When β-globin gene is mutated the drug treatments with Simvastatin, tBHQ, the combination of these two drugs, MS-275 and ST-20 suppress the levels of KLF1 mRNA and thereby BCL11A mRNA and protein, as a consequence increasing γ-globin mRNA and HbF levels. In vitro experiments in primary human erythroid cells showed that Simvastatin alone decreases KLF1 mRNA levels by approximately 20% of that seen in untreated cells, tBHQ alone by approximately 25%, and the combination of the two drugs by approximately 44% [16] . Drug treatments of erythroid progenitors cultured from sickle cell and β-thalassemia patients showed that MS-275 and ST-20 suppress KLF-1 mRNA by 3-and 2.5-fold, respectively [19] . Simulation results for concentration levels of KLF1 mRNA in untreated cells and in cells treated with the combination of Simvastatin and tBHQ, MS-275 and ST-20 are illustrated in Fig. 7(ad) , respectively. In all four cases KLF1 reaches the steady state at time point 25 pt, so that its concentration remain 8 It was reported that drug treatments with ST-20 in erythroid progenitors cultured from sickle cell anemia and beta thalassemia patients decrease HDAC1/2 mRNA levels by 6-fold of untreated control [19] . As it can be seen from [21] and SOX6 mRNA by 2.3-fold [20] . It was also observed variations in differentiation time and ACY-957 dosage affect the rate of suppression so that in another series of experiments BCL11A mRNA and SOX6 mRNA were suppressed by 2-and 10-fold, respectively [20, 21] . Simulation results for BCL11A and SOX6 are illustrated in Fig. 9 and Fig. 10 Finally, simulation results showed that treatments with our strategy decreases BCL11A mRNA concentration levels from 0.14 to 0.1 by 1.4-fold, SOX6 mRNA from 1.5 to 0.65 by 2.3-fold and ETF concentration levels from 3.1 to 0.31 (see Fig. 11 ), demonstrating decrease by 10-fold, over the untreated control.
Drug target prediction for β-globin disorders
Once the model validated next we determined the effects of drug treatments on γ-globin mRNA. Concentration levels of γ-globin mRNA for untreated cells as well as cells treated in accordence with strategies (1) to (6) Figure 11 . Simulation results for expression of ETF (a) in an untreated cell; and (b) in a treated one. ETF inhibition with our strategy decreases EFT concentration levels from 3.1 to 0.31, demonstrating decrease ETF concentration levels by 10-fold over the untreated control. These observations lead to the conclusion that the strategy proposed in the present research is the optimal among six strategies detailed in current work as it leads to the maximum increase of γ-globin mRNA levels.
Discussions
In the present study, we propose a multiprotein complex ETF as a target for drug discovery for β-globin disorders. Currently, multiprotein complexes are widely recognized as key targets for drug discovery though they tend to be more challenging targets than single protein targetting. Evidently, it is a real challenge to discover a small drug molecule that binds at the large and flat interfaces and disrupts the formation of multiprotein complexes. These kind of applications are largely avoided by many pharmaceutical companies. Another contradiction of drug discovery in practice is that while most regulatory proteins are components of multiprotein systems, pharmaceutical industry focus so much on the active sites of monomeric proteins. The question posed in [32] is whether this is really sustainable. Some attempts have been made by biotechnology companies [33] and academia [34] to set up work in this area. But perhaps more efforts are required for significant departure from conventional monomeric targets to multiprotein targets.
Conclusion
This paper exploits the relationship between reverse pharmacology and quantitative modelling with HFPN to the benefit of both fields. We demonstrate that a quantitative modelling with Petri net technologies can be efficiently implemented in target-based drug discovery. More specifically, we pose a hypothesis regarding protein and multiprotein 10 targets to discover a drug for β-globin disorders. In order to assess the precision of our prediction we create quantitative model of human fetal-to-adult hemoglobin switch network, use data from literature to validate the model and then perform simulations to compare our proposed strategy with already existing ones. When compared to the other strategies, our strategy results in maximum γ-globin gene induction which approves the consistency of the hypothesis.
